Identification of immunogenic and cross-reactive chikungunya virus-specific CD4+ T cell epitopes in chronic chikungunya viral arthritic disease in humans
Rimjhim AgarwaliD, Calvin HaiD, Fernanda Heloise CôrtesiD, Ye Ji LeeiD, Amparo Martínez-PéreziD, Rosa Isela GálveziD, Izabella N. CastilloiD, Elizabeth Jane PhillipsiD, Simon Alexander MallaliD, Ángel BalmasedaiD, Eva HarrisiD, Claudia M. Romero-VivasiD, Lakshmanane PremkumariD, Andrew K. I. FalconariD, Alba GrifoniiD, Alessandro SetteiD, Daniela WeiskopfiD
Abstract
Chikungunya virus (CHIKV), a mosquito-borne alphavirus, causes acute febrile illness that can progress into chronic chikungunya virus disease (CHIKVD) marked by persistent debilitating arthralgia. At present, the exact cause of chronic CHIKVD is not understood, and in humans, the targets of CD4+ T cells in CHIKV are currently unknown. Here, by stimulating peripheral blood mononuclear cells (PBMCs) collected from patients suffering from chronic CHIKVD with peptides spanning the entire CHIKV genome, we provide a comprehensive landscape of CHIKV CD4+ T cell epitopes. We identified 123 novel CD4+ T cell epitopes and three immunodominant regions in E1, nsP1 and CP proteins. The immunodominance of these E1, nsP1 and CP regions was mapped to optimal epitopes, characterized by the capacity to bind to many common HLA class II allelic variants. In addition, we designed and validated a new CHIKV-specific CD4+ T cell epitope megapool, spanning both structural and non-structural proteins, which can be a useful tool to study CHIKV-specific T cell responses in small blood volumes, typically available in pediatric or clinical samples. Finally, by in silico assessment of the conservation of the CHIKV proteome in a diverse set of alphaviruses, we defined CHIKV epitopes conserved across arthritogenic and encephalitic viruses. Overall, our work is the first to identify CD4+ T cell targets of CHIKV in humans, expanding our capacity to study the role of T cells in CHIKV pathogenesis and mapping targets of alphaviruses for vaccine design.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 11
- FWCI
- 3.03
- Field percentile
- top 7%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Chikungunya-virus-specific CD4+ T cells are associated with chronic chikungunya viral arthritic disease in humans
Rimjhim Agarwal, James Chang, … Daniela Weiskopf·Cell Reports MedicinePeer-reviewed·May 1, 2025
- Chikungunya virus infection disrupts MHC-I antigen presentation via nonstructural protein 2
Brian C. Ware, M. Guston Parks, … Thomas E. Morrison·PLoS PathogensPeer-reviewed·Mar 14, 2024
- A safe insect-based Chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques
Awadalkareem Adam, Courtney B. Woolsey, … Tian Wang·npj VaccinesPeer-reviewed·Dec 19, 2024
- Chikungunya virus glycoproteins transform macrophages into productive viral dissemination vessels.
M. M. H. Li, Z. Yao, … J. A. Wohlschlegel·bioRxiv·May 29, 2023
- Molecular basis for chikungunya virus recognition of a mosquito-specific receptor
Xiaoyi Fan, Wanyu Li, … Jonathan Abraham·bioRxiv·Jul 29, 2026
- Emerging chikungunya virus variants at the E1-E1 inter-glycoprotein spike interface impact virus attachment and Inflammation
M. Rangel, N. McAllister, … K. A. Stapleford·bioRxiv·Sep 13, 2021